Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Immuno-Oncology: Emerging Targets and Combination Therapies
Henry T. Marshall, Mustafa B.A. Djamgoz
Frontiers in Oncology (2018) Vol. 8
Open Access | Times Cited: 280

Showing 1-25 of 280 citing articles:

Engineering precision nanoparticles for drug delivery
Michael J. Mitchell, Margaret M. Billingsley, Rebecca M. Haley, et al.
Nature Reviews Drug Discovery (2020) Vol. 20, Iss. 2, pp. 101-124
Open Access | Times Cited: 5155
Peptide-Based Vaccines: Current Progress and Future Challenges
Ryan J. Malonis, Jonathan R. Lai, Olivia Vergnolle
Chemical Reviews (2019) Vol. 120, Iss. 6, pp. 3210-3229
Open Access | Times Cited: 493
The importance of exosomal PDL1 in tumour immune evasion
Dhouha Daassi, Kathleen M. Mahoney, Gordon J. Freeman
Nature reviews. Immunology (2020) Vol. 20, Iss. 4, pp. 209-215
Closed Access | Times Cited: 483
DNA Vaccines—How Far From Clinical Use?
Dominika Hobernik, Matthias Bros
International Journal of Molecular Sciences (2018) Vol. 19, Iss. 11, pp. 3605-3605
Open Access | Times Cited: 426
Impact of GPCR Structures on Drug Discovery
Miles Congreve, Chris de Graaf, Nigel A. Swain, et al.
Cell (2020) Vol. 181, Iss. 1, pp. 81-91
Open Access | Times Cited: 299
Clinical Pharmacokinetics and Pharmacodynamics of Immune Checkpoint Inhibitors
Maddalena Centanni, Dirk Jan A. R. Moes, Iñaki F. Trocóniz, et al.
Clinical Pharmacokinetics (2019) Vol. 58, Iss. 7, pp. 835-857
Open Access | Times Cited: 286
Tumor-Infiltrating Lymphocytes and Their Prognostic Value in Cutaneous Melanoma
Fabienne Maibach, Hassan Sadozai, S. Morteza Seyed Jafari, et al.
Frontiers in Immunology (2020) Vol. 11
Open Access | Times Cited: 234
Inflammation induced by incomplete radiofrequency ablation accelerates tumor progression and hinders PD-1 immunotherapy
Liangrong Shi, Junjun Wang, Nianhua Ding, et al.
Nature Communications (2019) Vol. 10, Iss. 1
Open Access | Times Cited: 200
Tebentafusp, A TCR/Anti-CD3 Bispecific Fusion Protein Targeting gp100, Potently Activated Antitumor Immune Responses in Patients with Metastatic Melanoma
Mark R. Middleton, Cheryl McAlpine, Victoria K. Woodcock, et al.
Clinical Cancer Research (2020) Vol. 26, Iss. 22, pp. 5869-5878
Open Access | Times Cited: 199
Bacterial Outer Membrane Vesicles Presenting Programmed Death 1 for Improved Cancer Immunotherapy via Immune Activation and Checkpoint Inhibition
Yao Li, Ruifang Zhao, Keman Cheng, et al.
ACS Nano (2020) Vol. 14, Iss. 12, pp. 16698-16711
Closed Access | Times Cited: 196
The BiTE (bispecific T‐cell engager) platform: Development and future potential of a targeted immuno‐oncology therapy across tumor types
Hermann Einsele, Hossein Borghaei, Robert Z. Orlowski, et al.
Cancer (2020) Vol. 126, Iss. 14, pp. 3192-3201
Open Access | Times Cited: 169
Therapeutic PD-L1 antibodies are more effective than PD-1 antibodies in blocking PD-1/PD-L1 signaling
Annika De Sousa Linhares, Claire Battin, Sabrina Jutz, et al.
Scientific Reports (2019) Vol. 9, Iss. 1
Open Access | Times Cited: 151
The IL-17 family in diseases: from bench to bedside
Longjie Huangfu, Ruiying Li, Yamei Huang, et al.
Signal Transduction and Targeted Therapy (2023) Vol. 8, Iss. 1
Open Access | Times Cited: 145
Combined anti‐PD‐1 and anti‐CTLA‐4 checkpoint blockade: Treatment of melanoma and immune mechanisms of action
Zena Willsmore, Ben G T Coumbe, Silvia Crescioli, et al.
European Journal of Immunology (2021) Vol. 51, Iss. 3, pp. 544-556
Open Access | Times Cited: 139
Review of the Immune Checkpoint Inhibitors in the Context of Cancer Treatment
Norah A. Alturki
Journal of Clinical Medicine (2023) Vol. 12, Iss. 13, pp. 4301-4301
Open Access | Times Cited: 55
Imidazole‐Based Synthetic Lipidoids for In Vivo mRNA Delivery into Primary T Lymphocytes
Xuewei Zhao, Jinjin Chen, Min Qiu, et al.
Angewandte Chemie International Edition (2020) Vol. 59, Iss. 45, pp. 20083-20089
Closed Access | Times Cited: 127
The role of neoantigen in immune checkpoint blockade therapy
Ming Yi, Shuang Qin, Weiheng Zhao, et al.
Experimental Hematology and Oncology (2018) Vol. 7, Iss. 1
Open Access | Times Cited: 119
First-in-class ruthenium anticancer drug (KP1339/IT-139) induces an immunogenic cell death signature in colorectal spheroids in vitro
Debora Wernitznig, Konstantinos Kiakos, Giorgia Del Favero, et al.
Metallomics (2019) Vol. 11, Iss. 6, pp. 1044-1048
Open Access | Times Cited: 113
Immunotherapies and Combination Strategies for Immuno-Oncology
Cody Barbari, Tyler Fontaine, Priyanka Parajuli, et al.
International Journal of Molecular Sciences (2020) Vol. 21, Iss. 14, pp. 5009-5009
Open Access | Times Cited: 100
Insights Into Lung Cancer Immune-Based Biology, Prevention, and Treatment
Sara Saab, Hussein Zalzale, Zahraa Rahal, et al.
Frontiers in Immunology (2020) Vol. 11
Open Access | Times Cited: 96
Highly Multiplexed Phenotyping of Immunoregulatory Proteins in the Tumor Microenvironment by CODEX Tissue Imaging
Darci J. Phillips, Christian M. Schürch, Michael S. Khodadoust, et al.
Frontiers in Immunology (2021) Vol. 12
Open Access | Times Cited: 91
Molecular imaging biomarkers for immune checkpoint inhibitor therapy
Pim P. van de Donk, Laura Kist de Ruijter, Marjolijn N. Lub–de Hooge, et al.
Theranostics (2020) Vol. 10, Iss. 4, pp. 1708-1718
Open Access | Times Cited: 90
Antibody and antibody fragments for cancer immunotherapy
Weizhi Chen, Yuan Yang, Xiqun Jiang
Journal of Controlled Release (2020) Vol. 328, pp. 395-406
Closed Access | Times Cited: 88
Harnessing the immune system against cancer: current immunotherapy approaches and therapeutic targets
Ayana R. Kumar, Aswathy R. Devan, Bhagyalakshmi Nair, et al.
Molecular Biology Reports (2021) Vol. 48, Iss. 12, pp. 8075-8095
Open Access | Times Cited: 88
Breast cancer immunotherapy: Current and novel approaches
Khadijeh Barzaman, Shima Moradi‐Kalbolandi, Aysooda Hosseinzadeh, et al.
International Immunopharmacology (2021) Vol. 98, pp. 107886-107886
Closed Access | Times Cited: 81
Page 1 - Next Page

Scroll to top